drugset / Trial / NCT00633529
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
Non-randomizedSingle-groupOpen-label
Summary
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
Timeline
- Start
- 2007-11
- Primary completion
- 2010-10
- Completion
- 2011-03
Publications
- Results Smith, D., P. Conkling, D. Richards, C. Alemany, T. Boyd, L. Garbo, D. Loesch, D. Wages, A. Bexon, J. Murphy. Phase 1 Study of the Toll-like Receptor (TLR9) Agonist, IMO-2055, Combined with Erlotinib and Bevacizumab in Patients with Advanced or Metastatic non-Small Cell Lung Cancer. ECCO-ESMO Annual Meeting, 2009. Abstract 9.148.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EMD 1201081 | Oligonucleotide (other) | 0.08 mg/kg | Subcutaneous |
| Subject | EMD 1201081 | Oligonucleotide (other) | 0.16 mg/kg | Subcutaneous |
| Subject | EMD 1201081 | Oligonucleotide (other) | 0.32 mg/kg | Subcutaneous |